Related Experiment Video
Updated: May 29, 2026
07:38
A General Method for Detecting Nitrosamide Formation in the In Vitro Metabolism of Nitrosamines by Cytochrome P450s
Published on: September 25, 2017
Novel advances in cytochrome P450 research
Deepika Singh1, Akriti Kashyap, Ram Vinay Pandey
1Department of Biotechnology and Bioinformatics, Ranbaxy Research Laboratories, R&D III, Sec 18, Udyog Vihar, Gurgaon 122015, Haryana, India. deepika.singh.ea@dsin.co.in
Drug Discovery Today
|August 26, 2011
Summary
Cytochrome P450 (CYP) enzyme regulation by microRNAs offers new insights into drug metabolism and response variability. Understanding these mechanisms aids in personalized medicine and drug development.
Area of Science:
- Pharmacogenomics
- Molecular Biology
- Drug Metabolism
Background:
- Cytochrome P450 (CYP) enzymes are crucial for drug metabolism and determine drug half-life.
- Genetic variations (polymorphisms) in CYP genes cause significant variability in drug response.
- MicroRNAs (miRNAs) are newly identified regulators of CYP gene expression.
Purpose of the Study:
- To review recent advances in understanding microRNA-mediated regulation of CYP enzymes.
- To explore novel perspectives on CYP gene regulation mechanisms.
- To discuss the implications of CYP genotyping technologies for personalized medicine.
Main Methods:
- Literature review of studies on CYP gene regulation by microRNAs.
- Analysis of molecular mechanisms underlying CYP expression.
- Evaluation of current and emerging CYP genotyping technologies.
Main Results:
- MicroRNA regulation significantly impacts CYP enzyme activity and drug metabolism.
- Understanding these regulatory networks explains individual differences in drug response.
- Advances in genotyping enable more precise prediction of drug efficacy and toxicity.
Conclusions:
- MicroRNA-mediated regulation of CYPs is a key factor in drug response variability.
- Integrated understanding of CYP regulation and genotyping offers therapeutic opportunities.
- These insights advance personalized medicine and the development of targeted therapies.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:17Drug Metabolism: Phase I Reactions
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
01:19Factors Affecting Drug Biotransformation: Biological
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...